The New Identified Biomarkers Determine Sensitivity to Immune Check-Point Blockade Therapies in Melanoma

OncoImmunology - United States
doi 10.1080/2162402x.2019.1608132
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Systemic Immunological Biomarkers of Clinical Responses in Immune Checkpoint Blockade Therapies

Lung Cancer Management
2018English

H3K27me3 and EZH2 Expression in Melanoma: Relevance for Melanoma Progression and Response to Immune Checkpoint Blockade

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2020English

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Cancer Cell
Cancer ResearchOncologyCell Biology
2018English

B Cells Sustain Inflammation and Predict Response to Immune Checkpoint Blockade in Human Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

Diffuse Large B-Cell Lymphoma: Using Immune Biomarkers to Define Novel Therapies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Is There a Role for Immune Checkpoint Blockade in Metastatic Uveal Melanoma?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma

Oncotarget
Oncology
2011English

Genomics of Immune Diseases and New Therapies

Annual Review of Immunology
AllergyImmunology
2016English

784 a New Immune Evasion Mechanism in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy